• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CA125用于诊断晚期膀胱尿路上皮癌：一项系统评价和荟萃分析

CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis.

作者信息

Lin Hsuan-Jen, Hu Rouh-Mei, Chen Hung-Chih, Lin Chung-Chih, Lee Chi-Yu, Chou Che-Yi

机构信息

Division of Nephrology, Asia University Hospital, Taichung 41354, Taiwan.

Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan.

出版信息

Cancers (Basel). 2023 Jan 28;15(3):813. doi: 10.3390/cancers15030813.

DOI:10.3390/cancers15030813
PMID:36765770
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9913454/
Abstract

BACKGROUND

Urothelial carcinoma of the bladder (UCB) is the second most common genitourinary cancer. This study aims to assess the diagnostic accuracy of CA125 in advanced UCB.

METHODS

We searched prevalent studies in PubMed, the Cochrane Library, Scopus, Embase, the Web of Science China National Knowledge Infrastructure database, and Wanfang data before October 2022. Pooled sensitivity, specificity, and summary receiver operating characteristics were used to assess the diagnostic value of CA125.

RESULTS

One thousand six hundred forty-one patients from 14 studies were analyzed. UCB stage T3-4N1 was defined as advanced UCB in ten studies; T2-4 was used in three studies; and N1M1 in one study. Patients' age was between 21 to 92, and 21% to 48.6% of patients were female. The pooled sensitivity was 0.695 (95% confidence interval (CI): 0.426-0.875). The pooled specificity was 0.846 (95% CI: 0.713-0.924). The diagnostic odds ratio was 8.138 (95% CI: 4.559-14.526). The AUC was 0.797.

CONCLUSION

CA125 may provide significant diagnostic accuracy in identifying muscle-invasive, lymph node-involved, and distant metastatic tumors in patients with urothelial carcinoma of the bladder. Limited studies have been conducted on the prognostic role of CA125. More studies are needed for a meta-analysis on the prognostic role of CA125 in UCB.

摘要

背景

膀胱尿路上皮癌（UCB）是第二常见的泌尿生殖系统癌症。本研究旨在评估CA125在晚期UCB中的诊断准确性。

方法

我们检索了截至2022年10月在PubMed、Cochrane图书馆、Scopus、Embase、中国科学引文数据库和万方数据中发表的相关研究。采用合并敏感性、特异性和汇总受试者工作特征曲线来评估CA125的诊断价值。

结果

对来自14项研究的1641例患者进行了分析。在10项研究中，UCB分期T3 - 4N1被定义为晚期UCB；3项研究采用T2 - 4；1项研究采用N1M1。患者年龄在21至92岁之间，21%至48.6%的患者为女性。合并敏感性为0.695（95%置信区间（CI）：0.426 - 0.875）。合并特异性为0.846（95% CI：0.713 - 0.924）。诊断比值比为8.138（95% CI：4.559 - 14.526）。曲线下面积（AUC）为0.797。

结论

CA125在识别膀胱尿路上皮癌患者的肌层浸润性、淋巴结受累及远处转移性肿瘤方面可能具有显著的诊断准确性。关于CA125预后作用的研究有限。需要更多研究对CA125在UCB中的预后作用进行荟萃分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/693151696c94/cancers-15-00813-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/7cd1a3560dfc/cancers-15-00813-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/a3b657a8b857/cancers-15-00813-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/96565c79329b/cancers-15-00813-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/85937cc35117/cancers-15-00813-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/693151696c94/cancers-15-00813-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/7cd1a3560dfc/cancers-15-00813-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/a3b657a8b857/cancers-15-00813-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/96565c79329b/cancers-15-00813-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/85937cc35117/cancers-15-00813-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d77/9913454/693151696c94/cancers-15-00813-g005.jpg

相似文献

1
CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis.CA125用于诊断晚期膀胱尿路上皮癌：一项系统评价和荟萃分析
Cancers (Basel). 2023 Jan 28;15(3):813. doi: 10.3390/cancers15030813.
2
Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for the diagnosis of urinary bladder cancer.长链非编码RNA尿路上皮癌相关1作为诊断膀胱癌的肿瘤生物标志物。
Tumour Biol. 2017 Jun;39(6):1010428317709990. doi: 10.1177/1010428317709990.
3
Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis.基于CA125的生物标志物组在胰腺癌患者中的诊断准确性：一项系统评价和荟萃分析
J Cancer. 2017 Oct 9;8(17):3615-3622. doi: 10.7150/jca.18901. eCollection 2017.
4
Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis.根治性膀胱切除术治疗膀胱癌患者术前血液生物标志物的预后价值：系统评价和荟萃分析。
Int J Clin Oncol. 2020 Aug;25(8):1459-1474. doi: 10.1007/s10147-020-01690-1. Epub 2020 May 26.
5
Diagnostic accuracy of MUC7 expression for bladder cancer: A systematic review and meta-analysis.MUC7 表达对膀胱癌的诊断准确性：系统评价和荟萃分析。
Medicine (Baltimore). 2023 Sep 1;102(35):e34828. doi: 10.1097/MD.0000000000034828.
6
Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study.膀胱尿路上皮癌既往史对上尿路尿路上皮癌患者的预后价值：一项回顾性多中心研究结果
World J Urol. 2015 Jul;33(7):1005-13. doi: 10.1007/s00345-014-1363-9. Epub 2014 Jul 22.
7
Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.上皮性卵巢癌患者卵巢恶性肿瘤风险的诊断措施比较：一项荟萃分析。
Sci Rep. 2021 Aug 27;11(1):17308. doi: 10.1038/s41598-021-96552-9.
8
Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes.膀胱肉瘤样变型尿路上皮癌：临床病理特征及生存结局的系统评价和荟萃分析
Cancer Cell Int. 2020 Nov 14;20(1):550. doi: 10.1186/s12935-020-01626-9.
9
Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis.性别对根治性手术治疗上尿路上皮癌和膀胱癌结局影响的差异：系统评价和荟萃分析。
J Urol. 2020 Jul;204(1):58-62. doi: 10.1097/JU.0000000000000788. Epub 2020 Jan 29.
10
Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.卵巢恶性肿瘤风险算法是否优于人附睾蛋白 4 和 CA125 预测上皮性卵巢癌：一项荟萃分析。
BMC Cancer. 2012 Jun 19;12:258. doi: 10.1186/1471-2407-12-258.

引用本文的文献

1
Epigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma.表观遗传调控在尿路上皮癌中引发自然杀伤细胞介导的免疫反应。
Mol Med. 2025 Jun 24;31(1):247. doi: 10.1186/s10020-025-01264-9.
2
Recent advances in surface plasmon resonance for the detection of ovarian cancer biomarkers: a thorough review.表面等离子体共振在卵巢癌生物标志物检测中的最新进展：全面综述。
Mikrochim Acta. 2024 Oct 9;191(11):659. doi: 10.1007/s00604-024-06740-3.
3
A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.

本文引用的文献

1
Cancer statistics, 2022.癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
2
Clinical effect of robot-assisted radical cystectomy in bladder cancer.机器人辅助根治性膀胱切除术治疗膀胱癌的临床疗效
Am J Transl Res. 2021 Sep 15;13(9):10545-10553. eCollection 2021.
3
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
长读测序技术推动卵巢癌生物标志物 CA125（MUC16）分子模型的修订。
Cancer Res Commun. 2024 Jan 31;4(1):253-263. doi: 10.1158/2767-9764.CRC-23-0327.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
Bladder Cancer: A Review.膀胱癌：综述。
JAMA. 2020 Nov 17;324(19):1980-1991. doi: 10.1001/jama.2020.17598.
5
Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis.采用膀胱影像报告和数据系统（VI-RADS）检测膀胱癌的肌肉侵犯：一项诊断性荟萃分析。
Eur Radiol. 2020 Aug;30(8):4606-4614. doi: 10.1007/s00330-020-06802-z. Epub 2020 Apr 2.
6
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.采用超深度血浆游离 DNA 测序对膀胱癌患者进行转移性复发的早期检测和治疗效果监测。
J Clin Oncol. 2019 Jun 20;37(18):1547-1557. doi: 10.1200/JCO.18.02052. Epub 2019 May 6.
7
Diagnostic test accuracy: application and practice using R software.诊断测试准确性：使用 R 软件的应用与实践。
Epidemiol Health. 2019;41:e2019007. doi: 10.4178/epih.e2019007. Epub 2019 Mar 28.
8
Development and validation of a nomogram for urothelial cancer in patients with chronic kidney disease.构建并验证用于慢性肾脏病患者尿路上皮癌的列线图
Sci Rep. 2019 Mar 5;9(1):3473. doi: 10.1038/s41598-019-40276-4.
9
Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer.膀胱尿路上皮癌新辅助化疗后膀胱切除术前上皮肿瘤标志物反应与肿瘤学结局之间的关联
Urol Oncol. 2019 Jan;37(1):1-11. doi: 10.1016/j.urolonc.2018.09.008. Epub 2018 Nov 20.
10
Diagnostic biomarkers in non-muscle invasive bladder cancer.非肌层浸润性膀胱癌的诊断生物标志物。
World J Urol. 2019 Oct;37(10):2009-2016. doi: 10.1007/s00345-018-2567-1. Epub 2018 Nov 22.